Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
SCYNEXIS, Inc is a drug manufacturers-specialty & generic business based in the US. SCYNEXIS shares (SCYX) are listed on the NASDAQ and all prices are listed in US Dollars. SCYNEXIS employs 27 staff and has a market cap (total outstanding shares value) of USD$69.9 million.
|Latest market close||USD$5.84|
|52-week range||USD$4.201 - USD$11.7|
|50-day moving average||USD$5.3571|
|200-day moving average||USD$6.2968|
|Wall St. target price||USD$36|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.587|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||N/A|
|1 month (2020-11-06)||19.18%|
|3 months (2020-09-02)||N/A|
|6 months (2020-06-02)||N/A|
|1 year (2019-12-02)||N/A|
|2 years (2018-12-02)||N/A|
|3 years (2017-12-02)||N/A|
|5 years (2015-12-02)||N/A|
|Gross profit TTM||USD$121,000|
|Return on assets TTM||-88.42%|
|Return on equity TTM||-343.06%|
|Market capitalisation||USD$69.9 million|
TTM: trailing 12 months
There are currently 203,421 SCYNEXIS shares held short by investors – that's known as SCYNEXIS's "short interest". This figure is 3.4% down from 210,586 last month.
There are a few different ways that this level of interest in shorting SCYNEXIS shares can be evaluated.
SCYNEXIS's "short interest ratio" (SIR) is the quantity of SCYNEXIS shares currently shorted divided by the average quantity of SCYNEXIS shares traded daily (recently around 69664.726027397). SCYNEXIS's SIR currently stands at 2.92. In other words for every 100,000 SCYNEXIS shares traded daily on the market, roughly 2920 shares are currently held short.
However SCYNEXIS's short interest can also be evaluated against the total number of SCYNEXIS shares, or, against the total number of tradable SCYNEXIS shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case SCYNEXIS's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 SCYNEXIS shares in existence, roughly 20 shares are currently held short) or 0.0227% of the tradable shares (for every 100,000 tradable SCYNEXIS shares, roughly 23 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against SCYNEXIS.
Find out more about how you can short SCYNEXIS stock.
We're not expecting SCYNEXIS to pay a dividend over the next 12 months.
SCYNEXIS's shares were split on a 1:10 basis on 17 July 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your SCYNEXIS shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for SCYNEXIS shares which in turn could have impacted SCYNEXIS's share price.
Over the last 12 months, SCYNEXIS's shares have ranged in value from as little as $4.201 up to $11.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while SCYNEXIS's is 1.8315. This would suggest that SCYNEXIS's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase 2 clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.